Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
Theodoros Karantanos(Johns Hopkins University), Timothy C. Thompson(The University of Texas MD Anderson Cancer Center)
Cited by 879
Related Papers
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma
|Cancer Cell|2020|142
Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer
|Nature Communications|2020|83
Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
|International Journal of Cancer|2017|50